Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of CoronaVac Booster in Healthy Adults (18-59 Years)
NCT04962308Phase 4Unknown
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Jun 2021
- Primary completion
- Aug 2021
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 4, open-label trial of coronavac in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Sinovac Biotech Ltd. Primary endpoints: Geometric Mean Titer of Neutralizing Antibody to Live SARS-CoV-2 and Safety Index - Incidence of Adverse Reactions. Status: unknown.
02
Drugs
coronavac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04962308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04962308.